Please assess the completion status of the following clinical trial:

Trial Title: Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* Japanese male or female patients with T2DM diagnosed for at least 1 year prior to the time of screening as established in the medical history.~* Patients aged 20 to 75 years at screening.~* Body mass index ≤35 kg/m\^2 at screening.~* Glycohemoglobin ≥7.0% and ≤10.0% at screening.~* Fasting C-peptide ≥0.6 ng/mL at screening.~Exclusion criteria:~* Diabetes other than T2DM.~* History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening.~* History of hypoglycemia unawareness.~* Hemoglobinopathy or hemolytic anemia.~* History of myocardial infarction, stroke, or heart failure, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period.~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.~* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment.~* Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).~* If female, pregnancy or breast-feeding.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine/ lixisenatide dose 1 Test 1 (Type: EXPERIMENTAL): Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
- Insulin glargine/ lixisenatide dose 2 Test 2 (Type: EXPERIMENTAL): Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
- Placebo - Reference 1 (Type: PLACEBO_COMPARATOR): Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
- Insulin glargine (Lantus) - Reference 2 (Type: OTHER): Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition

Based on this trial design, predict the completion outcome and termination type (if applicable).